- Home
- ATOS vs ANIX Comparison
ATOS vs ANIX Comparison
Compare ATOS & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- ANIX
- Stock Information
- Founded
- ATOS 2009
- ANIX 1982
- Country
- ATOS United States
- ANIX United States
- Employees
- ATOS N/A
- ANIX N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- ANIX Biotechnology: Pharmaceutical Preparations
- Sector
- ATOS Health Care
- ANIX Health Care
- Exchange
- ATOS Nasdaq
- ANIX Nasdaq
- Market Cap
- ATOS 107.2M
- ANIX 95.7M
- IPO Year
- ATOS 2012
- ANIX 1987
- Fundamental
- Price
- ATOS $0.84
- ANIX $2.94
- Analyst Decision
- ATOS Strong Buy
- ANIX Strong Buy
- Analyst Count
- ATOS 3
- ANIX 3
- Target Price
- ATOS $6.17
- ANIX $9.00
- AVG Volume (30 Days)
- ATOS 473.0K
- ANIX 62.5K
- Earning Date
- ATOS 11-11-2025
- ANIX 09-10-2025
- Dividend Yield
- ATOS N/A
- ANIX N/A
- EPS Growth
- ATOS N/A
- ANIX N/A
- EPS
- ATOS N/A
- ANIX N/A
- Revenue
- ATOS N/A
- ANIX N/A
- Revenue This Year
- ATOS N/A
- ANIX N/A
- Revenue Next Year
- ATOS N/A
- ANIX N/A
- P/E Ratio
- ATOS N/A
- ANIX N/A
- Revenue Growth
- ATOS N/A
- ANIX N/A
- 52 Week Low
- ATOS $0.55
- ANIX $2.07
- 52 Week High
- ATOS $1.66
- ANIX $4.20
- Technical
- Relative Strength Index (RSI)
- ATOS 60.84
- ANIX 43.29
- Support Level
- ATOS $0.81
- ANIX $2.93
- Resistance Level
- ATOS $0.80
- ANIX $3.09
- Average True Range (ATR)
- ATOS 0.03
- ANIX 0.11
- MACD
- ATOS 0.01
- ANIX 0.00
- Stochastic Oscillator
- ATOS 92.67
- ANIX 1.85
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.